Keyphrases
Homocysteine
100%
L-DOPA
100%
Parkinson Patients
100%
Plasma Parameters
100%
Entacapone
63%
Long-term Treatment
27%
Homocysteine Levels
27%
Plasma Homocysteine
27%
Cognitive Impairment
9%
Risk Factors
9%
Parkinson's Disease
9%
Naïve Patients
9%
Vascular Disease
9%
Neurodegenerative Diseases
9%
Cognitive Dementia
9%
3-group
9%
Additional Treatment
9%
Possible Sources
9%
Catechol-O-methyltransferase
9%
Catechol-O-methyltransferase Inhibitors
9%
Peripheral Metabolism
9%
Combined Treatment
9%
Combined Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Homocysteine
100%
DOPA
100%
Parkinson's Disease
100%
Entacapone
63%
Catechol
18%
Retrospective Study
9%
Cognitive Defect
9%
Methyltransferase Inhibitor
9%
Degenerative Disease
9%
Vascular Disease
9%
Methyltransferase
9%
Neuroscience
Parkinson's Disease
100%
L-DOPA
100%
Homocysteine
100%
Entacapone
63%
Methyltransferase
18%
Neurodegenerative Disorder
9%
Vascular Disease
9%
Cognitive Disorders
9%
Metabolic Pathway
9%
Biochemistry, Genetics and Molecular Biology
Blood Level
100%
Homocysteine
100%
O-Methyltransferase
20%
Retrospective Study
10%
Metabolic Pathway
10%
Enzyme
10%